137 related articles for article (PubMed ID: 38818888)
1. Efficacy and safety of fezolinetant for moderate to severe vasomotor symptoms associated with menopause among women in East Asia: a phase 3 randomized study (MOONLIGHT I).
Ruan X; Bai W; Ren M; Kim T; Lee JY; Chuang FC; Wang PH; He W; Ma X; Miyazaki K; Song N; Wang X; Yu Q
J Int Med Res; 2024 May; 52(5):3000605241247684. PubMed ID: 38818888
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial.
Depypere H; Timmerman D; Donders G; Sieprath P; Ramael S; Combalbert J; Hoveyda HR; Fraser GL
J Clin Endocrinol Metab; 2019 Dec; 104(12):5893-5905. PubMed ID: 31415087
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety of fezolinetant in Chinese women with vasomotor symptoms associated with menopause: the phase 3 open-label MOONLIGHT 3 clinical trial.
Yu Q; Ming F; Ma J; Cai Y; Wang L; Ren M; Zhang J; Ma X; Miyazaki K; He W; Wang X
J Int Med Res; 2024 May; 52(5):3000605241246624. PubMed ID: 38818887
[TBL] [Abstract][Full Text] [Related]
5. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.
Lederman S; Ottery FD; Cano A; Santoro N; Shapiro M; Stute P; Thurston RC; English M; Franklin C; Lee M; Neal-Perry G
Lancet; 2023 Apr; 401(10382):1091-1102. PubMed ID: 36924778
[TBL] [Abstract][Full Text] [Related]
6. A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause.
Fraser GL; Lederman S; Waldbaum A; Kroll R; Santoro N; Lee M; Skillern L; Ramael S
Menopause; 2020 Apr; 27(4):382-392. PubMed ID: 32102086
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of fezolinetant in alleviating vasomotor symptoms linked to Menopause.: A systematic review and Meta-Analysis.
Elnaga AAA; Alsaied MA; Elettreby AM; Ramadan A
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():142-152. PubMed ID: 38640780
[TBL] [Abstract][Full Text] [Related]
8. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
[TBL] [Abstract][Full Text] [Related]
10. Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis.
Chavez MP; Pasqualotto E; Ferreira ROM; Hohl A; de Moraes FCA; Schmidt PHS; Rodrigues ALSO; de Sa JR
Climacteric; 2024 Jun; 27(3):245-254. PubMed ID: 38619017
[TBL] [Abstract][Full Text] [Related]
11. Fezolinetant treatment of moderate-to-severe vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
Santoro N; Nappi RE; Neal-Perry G; English M; King DD; Yamaguchi Y; Ottery FD
Menopause; 2024 Apr; 31(4):247-257. PubMed ID: 38517210
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan.
Takamatsu K; Miki T; Miyazaki K; Hashimoto A; He W; Wang X
Climacteric; 2024 Jun; ():1-9. PubMed ID: 38864290
[TBL] [Abstract][Full Text] [Related]
13. Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).
Nappi RE; Johnson KA; Stute P; Blogg M; English M; Morga A; Scrine L; Siddiqui E; Ottery FD
Menopause; 2024 Jun; 31(6):512-521. PubMed ID: 38626380
[TBL] [Abstract][Full Text] [Related]
14. Systematic review of neurokinin-3 receptor antagonists for the management of vasomotor symptoms of menopause.
Cieri-Hutcherson NE; Marji EK; Hutcherson TC
Menopause; 2024 Apr; 31(4):342-354. PubMed ID: 38471077
[TBL] [Abstract][Full Text] [Related]
15. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.
Shapiro C M M; Cano A; Nappi RE; Santoro N; English ML; Mancuso S; Morga A; Siddiqui E; Valluri U; Ottery FD
Maturitas; 2024 Aug; 186():107999. PubMed ID: 38749864
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fezolinetant, a neurokinin-3 antagonist, in treating vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis.
Rahman UA; Kashif TB; Usman M; Rana M; Hasanain M; Anjum MU; Cheema HA; Jaffar H; Bhattarai P
Medicine (Baltimore); 2023 Dec; 102(50):e36592. PubMed ID: 38115258
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of fezolinetant for vasomotor symptoms in postmenopausal women: A systematic review and meta-analysis of randomized controlled trials.
Akhtar SMM; Ali A; Khan MS; Khan V; Fareed A; Saleem SZ; Mumtaz M; Ahsan MN; Iqbal S; Asghar MS
Int J Gynaecol Obstet; 2024 Apr; ():. PubMed ID: 38563867
[TBL] [Abstract][Full Text] [Related]
18. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
Cano A; Nappi RE; Santoro N; Stute P; Blogg M; English ML; Morga A; Scrine L; Siddiqui E; Ottery FD
BJOG; 2024 Feb; ():. PubMed ID: 38320967
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Fezolinetant for the Treatment of Menopause-Associated Vasomotor Symptoms: A Meta-analysis.
Bonga KN; Mishra A; Maiti R; Padhy BM; Meher BR; Srinivasan A
Obstet Gynecol; 2024 Mar; 143(3):393-402. PubMed ID: 38227939
[TBL] [Abstract][Full Text] [Related]
20. Validation and Application of Thresholds to Define Meaningful Change in Vasomotor Symptoms Frequency: Analysis of Pooled SKYLIGHT 1 and 2 Data.
Morga A; Zimmermann L; Valluri U; Siddiqui E; McLeod L; Bender RH
Adv Ther; 2024 May; ():. PubMed ID: 38775925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
